An Open-Label, Randomized, Crossover Study to the Dose Proportionality of RSG XR in Healthy Volunteers in Fasting Conditions
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 May 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2008 New trial record.